• $18.5M
    Market Cap
  • -40.93%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-23.3M
-42.07%
-40.2M
-34.58%
-61.4M
-28.63%
-86.1M
-26.87%
Depreciation and Amortization Expense
728,000
-76.37%
3.1M
-17.20%
3.7M
+1.14%
3.7M
+138.43%
Total Operating Expenses
19.9M
-20.46%
25.0M
-39.90%
41.6M
-15.73%
49.3M
-17.84%
Operating Profit
-49.3M
-29.98%
-70.4M
-35.05%
-108.4M
-21.68%
-138.4M
-25.49%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
-100.00%
Total Nonoperating Income and Expense
3.8M
-33.00%
5.6M
-10.97%
6.3M
N/A
N/A
N/A
Income before Taxes
-49.3M
-29.98%
-70.4M
-35.05%
-108.4M
-21.68%
-138.4M
-25.49%
Income Taxes
0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
6.1M
+17.43%
5.2M
-2.91%
5.4M
N/A
0
N/A
Net Income
-45.5M
-29.71%
-64.8M
-36.54%
-102.1M
-25.02%
-136.1M
-26.57%
Net Income from Continuing Operations Applicable to Common
-45.5M
-29.71%
-64.8M
-36.54%
-102.1M
-25.02%
-136.1M
-26.57%
Basic EPS and Net Income
-14.35
+1,241.12%
-1.07
-42.47%
-1.86
-25.60%
-2.50
-28.16%
Diluted EPS and Net Income
-14.35
+1,241.12%
-1.07
-42.47%
-1.86
-25.60%
-2.50
-28.16%
Basic Weighted Average Shares
3.2M
-94.75%
60.4M
+10.34%
54.7M
+0.58%
54.4M
+2.03%
Diluted Weighted Average Shares
3.2M
-94.75%
60.4M
+10.34%
54.7M
+0.58%
54.4M
+2.03%
Balance Sheet
Cash and Cash Equivalents
46.3M
+23.23%
37.6M
+73.08%
21.7M
-37.26%
34.6M
-73.17%
Short-Term Investments
0
-100.00%
39.2M
-57.68%
92.6M
-40.27%
155.0M
-17.02%
Cash and Cash Equivalents and Short-Term Investments
46.3M
-39.68%
76.8M
-32.84%
114.3M
-39.72%
189.6M
-39.95%
Total Current Assets
47.8M
-39.40%
78.8M
-33.18%
118.0M
-40.14%
197.0M
-39.38%
Accumulated Depreciation
3.9M
-59.72%
9.7M
+34.38%
7.2M
+40.42%
5.2M
+108.03%
Property and Plant and Equipment and Net
4.1M
-55.99%
9.3M
-38.99%
15.3M
-32.07%
22.5M
-5.42%
Total Long-Term Assets
244,000
-47.30%
463,000
+6.93%
433,000
-89.85%
4.3M
-31.22%
Total Assets
62.3M
-39.19%
102.4M
-31.97%
150.5M
-38.19%
243.5M
-31.41%
Income Taxes Payable
3.0M
-31.52%
4.4M
-23.78%
5.8M
-30.75%
8.4M
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
23.1M
+19.21%
19.4M
+18.49%
16.3M
-10.95%
18.4M
-37.79%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
20.4M
-6.17%
21.8M
-4.94%
22.9M
-15.21%
27.0M
+65,831.71%
Total Liabilities
43.5M
+5.77%
41.2M
+4.81%
39.3M
-6.92%
42.2M
+15.83%
Retained Earnings
-704.8M
+6.91%
-659.2M
+10.89%
-594.5M
+20.73%
-492.4M
+38.21%
Total Stockholders Equity
18.8M
-69.39%
61.3M
-44.95%
111.3M
-44.74%
201.4M
-36.81%
Total Shares Outstanding
3.2M
-94.87%
62.1M
+12.95%
54.9M
+0.60%
54.6M
+0.68%
Cash Flow
Cash from Operating Activities
-31.5M
-34.30%
-48.0M
-38.73%
-78.3M
-33.79%
-118.2M
-6.83%
Capital Expenditures
34,000
0.00%
34,000
-76.71%
146,000
-93.58%
2.3M
-87.11%
Cash from Investing Activities
40.2M
-26.81%
54.9M
-15.77%
65.2M
+158.89%
25.2M
+155.00%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
23,000
-99.74%
8.9M
+6,473.33%
135,000
+109.98%
-1.4M
-100.81%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-55.28%
+7.95%
-51.21%
-1.14%
-51.80%
+13.89%
-45.48%
-16.21%
Return on Equity
-113.78%
+51.56%
-75.07%
+14.99%
-65.29%
+24.71%
-52.35%
-11.98%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
2.07
-49.17%
4.07
-43.61%
7.22
-32.77%
10.74
-2.56%
Cash Ratio
2.01
+3.37%
1.94
+46.07%
1.33
-29.54%
1.89
-56.87%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow